Table 2.
Adverse events recorded in SLE patients who received sirolimus treatment.
| Adverse event | Incidence n (%)a |
|
|---|---|---|
| PUMCH n = 49 |
Literature review n = 127 |
|
| Infection | 3 (6.1) | 5 (3.9) |
| Leukopenia | 2 (4.1) | 4 (3.1) |
| Allergic symptoms | 2 (4.1) | 3 (2.4) |
| Thrombocytopenia | 1 (2.0) | 0 |
| Peripheral oedema | 1 (2.0) | 2 (1.6) |
| Gastrointestinal symptoms | 1 (2.0) | 9 (7.1) |
| Mucosal ulcer | 1 (2.0) | 1 (0.8) |
| Dyslipidaemia | NA | 10 (7.9) |
| Anaemia | 0 | 4 (3.1) |
| Elevated liver enzymes | 0 | 1 (0.8) |
| Malignant tumour | 0 | 3 (2.4) |
| Headache | 0 | 2 (1.6) |
a
Data from PUMCH and Literature review were compared by chi-square test or Fisher’s exact test, where appropriate, and the p values for each adverse event were all found to be >0.1.
NA, not applicable; PUMCH, Peking Union Medical College Hospital.